Testing effectiveness (Phase 2)Study completedNCT00006475What this trial is testingSTI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast CrisisWho this might be right forLeukemia Novartis
Testing effectiveness (Phase 2)Active Not RecruitingNCT01424982What this trial is testingCombination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaWho this might be right forAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in Complete Remission+4 more M.D. Anderson Cancer Center 88
Testing effectiveness (Phase 2)Study completedNCT00982488What this trial is testingLong-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaWho this might be right forLeukemia Bristol-Myers Squibb 238
Early research (Phase 1)Active Not RecruitingNCT03233854What this trial is testingCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell MalignanciesWho this might be right forB Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+1 more Stanford University 56
Testing effectiveness (Phase 2)UnknownNCT04688983What this trial is testingStudy in Adult Ph-positive ALLWho this might be right forAcute Lymphoblastic Leukemia, Adult Cardiff University 180
Early research (Phase 1)Study completedNCT00005092What this trial is testingChemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more M.D. Anderson Cancer Center 7
Testing effectiveness (Phase 2)Looking for participantsNCT01746836What this trial is testingPonatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibWho this might be right forChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00363649What this trial is testingInterferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKIWho this might be right forLeukemia Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 36
Large-scale testing (Phase 3)Study completedNCT01511289What this trial is testingRadotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsWho this might be right forLeukemiaLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL Positive+3 more Il-Yang Pharm. Co., Ltd. 242
Large-scale testing (Phase 3)UnknownNCT00025402What this trial is testingChemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous LeukemiaWho this might be right forLeukemia III. Medizinische Klinik Mannheim 1,000
Large-scale testing (Phase 3)UnknownNCT00002869What this trial is testingInterferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous LeukemiaWho this might be right forLeukemia Medical Research Council 800
Testing effectiveness (Phase 2)Study completedNCT00482703What this trial is testingDasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid LeukemiaWho this might be right forMyeloid Leukemia, Chronic Bristol-Myers Squibb 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07443488What this trial is testingEfficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALLWho this might be right forHSCTPh+ ALL Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Ended earlyNCT00038649What this trial is testingTherapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-CWho this might be right forMyelogenous Leukemia, Chronic, Chronic Phase M.D. Anderson Cancer Center 117
Testing effectiveness (Phase 2)WithdrawnNCT01670084What this trial is testingNilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous LeukemiaWho this might be right forB-cell Adult Acute Lymphoblastic LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+2 more Mayo Clinic
Early research (Phase 1)Looking for participantsNCT03595917What this trial is testingABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLWho this might be right forB-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL Marlise Luskin, MD 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05931757What this trial is testingOlverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALLWho this might be right forPhiladelphia-Positive ALL The First Affiliated Hospital of Soochow University 22
Testing effectiveness (Phase 2)Study completedNCT02523976What this trial is testingDasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaWho this might be right forAcute,Leukemia, Lymphoid Institute of Hematology & Blood Diseases Hospital, China 30
Post-approval studies (Phase 4)Study completedNCT01735955What this trial is testingStudy to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored StudyWho this might be right forChronic Myelogenous Leukemia (CML)Metastatic Gastrointestinal Stromal Tumors (GIST)Acute Lymphoblastic Leukemia (ALL)+1 more Novartis Pharmaceuticals 57
Early research (Phase 1)Study completedNCT00064233What this trial is testingBMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib MesylateWho this might be right forLeukemia Jonsson Comprehensive Cancer Center 42